PTJ
NKTR icon

Paul Tudor Jones’s Nektar Therapeutics NKTR Stock Holding History

Paul Tudor Jones’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.35M Buy
33,600
+29,500
+720% +$2.16M ﹤0.01% 1838
2026
Q1 		$295K Buy
+4,100
New +$233K ﹤0.01% 3147

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paul Tudor Jones's NKTR Position: Q2 2026 in Review

Paul Tudor Jones sold out of Nektar Therapeutics (NKTR) in Q2 2026, closing a stake of 14,984 shares — an estimated $1.1M sold.

Paul Tudor Jones first reported a position in NKTR in Q4 2014 and held it in 29 quarters. The position peaked at $5.33M in Q2 2018. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Paul Tudor Jones reported no remaining Nektar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 14,984 Nektar Therapeutics shares in Q2 2026, an estimated $1.1M.
  • Paul Tudor Jones first reported a position in Nektar Therapeutics in Q4 2014 and held it in 29 quarters.
  • Paul Tudor Jones's Nektar Therapeutics position peaked at $5.33M in Q2 2018.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.